Get the Stockscreener App
4.45
1.77%
-0.08
Precigen Inc stock is traded at $4.45, with a volume of 4.55M.
It is down -1.77% in the last 24 hours and up +9.07% over the past month.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
See More
Previous Close:
$4.53
Open:
$4.57
24h Volume:
4.55M
Relative Volume:
1.01
Market Cap:
$1.59B
Revenue:
$9.68M
Net Income/Loss:
$-250.64M
P/E Ratio:
-3.179
EPS:
-1.3998
Net Cash Flow:
$-89.83M
1W Performance:
+24.30%
1M Performance:
+9.07%
6M Performance:
+20.60%
1Y Performance:
+192.76%
1-Day Range:
$4.4099
$4.71
1-Week Range:
$3.51
$4.71
52-Week Range:
$1.38
$5.465
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen Inc
Sector
Industry
Phone
301-556-9900
Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
4.45 | 1.59B | 9.68M | -250.64M | -89.83M | -1.3998 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-22-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-23-23 | Initiated | JP Morgan | Neutral |
| Nov-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-21 | Initiated | Stifel | Buy |
| Feb-22-21 | Initiated | Wells Fargo | Overweight |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| May-08-20 | Initiated | H.C. Wainwright | Buy |
View All
Precigen Inc Stock (PGEN) Latest News
Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares? - The Motley Fool
Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices - PR Newswire
Precigen jumps after Q1 beat as Papzimeos launch momentum takes hold - MSN
Precigen (NASDAQ:PGEN) Share Price Crosses Below 200-Day Moving AverageWhat's Next? - MarketBeat
PGEN: Durable RRP therapy drives rapid uptake, with global expansion and oncology pipeline advancing - TradingView
Precigen, Inc. (PGEN) is a great momentum stock: Should you buy? - MSN
PGEN News | PRECIGEN INC (NASDAQ:PGEN) - ChartMill
Precigen, Inc.'s (NASDAQ:PGEN) Path To Profitability - Moomoo
Have Precigen Insiders Been Selling Stock? - simplywall.st
H.C. Wainwright reiterates Precigen stock rating on trial data - Investing.com UK
H.C. Wainwright reiterates Precigen stock rating on trial data By Investing.com - Investing.com Australia
H.C. Wainwright Maintains Precigen(PGEN.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Precigen CCO Phil Tennant sells $131,985 in stock By Investing.com - Investing.com Australia
Precigen CFO Harry Thomasian Jr. sells $182,614 in stock - Investing.com UK
Precigen CEO Helen Sabzevari sells $519,930 in company stock - Investing.com UK
Precigen CEO Helen Sabzevari sells $519,930 in company stock By Investing.com - Investing.com South Africa
Precigen chief legal officer Lehr sells $127,011 in stock By Investing.com - Investing.com India
Precigen COO Rutul R Shah sells $186,185 in common stock By Investing.com - Investing.com India
Precigen chief legal officer Lehr sells $127,011 in stock - Investing.com
Precigen CFO Harry Thomasian Jr. sells $182,614 in stock By Investing.com - Investing.com Australia
Precigen COO Rutul R Shah sells $186,185 in common stock - Investing.com
Precigen CCO Phil Tennant sells $131,985 in stock - Investing.com
Precigen (PGEN) CEO sells 119,250 shares in tax sell-to-cover transaction - Stock Titan
Precigen (PGEN) CFO sells 41,884 shares to cover RSU tax withholding - Stock Titan
PRECIGEN (PGEN) CCO sells 30,272 shares in tax-related transaction - Stock Titan
Precigen (PGEN) COO sells 42,703 shares to cover RSU tax withholding - Stock Titan
Precigen (PGEN) Chief Legal Officer sells shares to cover RSU tax withholding - Stock Titan
Precigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Promising Long-Term Data for Precigen (PGEN) in RRP Treatment - GuruFocus
Precigen Q1 earnings call highlights - MSN
PGEN Q1 2026 Earnings: EPS Surprises Positive Despite No RevenueEnergy Earnings Report - newsline.com
Number of shareholders of Precigen, Inc. – NASDAQ:PGEN - TradingView
Number of shareholders of Precigen Inc – BX:I5X - TradingView
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years - PR Newswire
Precigen (PGEN) price target increased by 11.76% to 9.69 - MSN
Precigen Inc Stock (PGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.04%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):